Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 60 years.~* African in China.~* Able to understand the content of informed consent and willing to sign the informed consent~* Able and willing to complete all the secluded study process during the whole study follow-up period (about 1 month).~* A body mass index (BMI) 18.5-35.0 kg/m2~* Hemoglobin ≥110g/L for female, and ≥120g/L for male.~* White blood cells (WBC) 4.0-10.0×109 cells/L~* Total lymphocyte Count 0.8-4.5×109 cells/L~* Platelets 100-300×109 cells/L~* Alanine aminotransferase (ALT) 0-40U/L~* Serum creatinine 44-106μmol/L~* Active partial thromboplastin time (APTT) 20-40 seconds~* Prothrombin time (PT) 10-14 seconds~* Negative in HIV diagnostic blood test~* Axillary temperature ≤37.0°C on the day of enrollment~* General good health as established by medical history and physical examination.~Exclusion Criteria:~* Family history of seizure, epilepsy, brain or mental disease~* Participant that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV, such as mannitol.~* Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months~* Any acute fever disease or infections in last 7 days~* Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last one year~* Asplenia or functional asplenia~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of blood or needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- low dose (Type: EXPERIMENTAL): 30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
- High dose (Type: EXPERIMENTAL): After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete